Barry N. Kreiswirth, Ph.D.

Professor
Center for Discovery and Innovation, Hakensack Meridian Health

Disclosure(s): No financial relationships to disclose

Poster(s):

• (P-775) Unlocking Synergistic Potency: Dual Action of β-Lactam and β-Lactamase Inhibitor in Combating Mycobacterium abscessus through β-Lactamase Inhibition and Multi-Target Receptor Inactivation
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-788) Exploring β-Lactam Interactions with DacB1: Unraveling Optimal Therapies for Combating Drug-Resistant Mycobacterium tuberculosis
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-861) CTX-M-15-producing H30 ST131 Escherichia coli contributes to carbapenem use for E. coli bloodstream infections in the United States
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1503) Dual β-Lactam Approach for Treatment of Mycobacterium abscessus Infections in Adults – Results in 19 Patients
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-2320) Clinical Significance of Colonization with Fluoroquinolone-Resistant Enterobacterales in Hematopoietic Cell Transplant Recipients and Patients with Acute Leukemia
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT